Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Herceptin
Biotech
ESMO: Zymeworks lays down marker in fight to unseat Herceptin
Zymeworks presented encouraging early data on its HER2‑targeted bispecific antibody—and a showdown with the incumbent Herceptin is up next.
Nick Paul Taylor
Sep 16, 2021 8:50am
Byondis ready to link up to bring Herceptin-booster to market
Jun 8, 2021 12:25pm
MacroGenics chief medical officer hits the exit
Mar 5, 2020 7:54am
Seattle Genetics nabs FDA breakthrough tag for tucatinib
Dec 18, 2019 8:55am
AstraZeneca, Daiichi's ADC keeps breast cancer at bay
Dec 11, 2019 8:00am
Bolt Bio preps trials of immune-stimulating cancer drug
Nov 11, 2019 9:36am
